» Articles » PMID: 33350747

Effects of Microvascular Invasion on Clinical Outcomes After Resection with Curative Intent for Cholangiocarcinoma

Overview
Specialty General Medicine
Date 2020 Dec 22
PMID 33350747
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Surgery is the only curative treatment for cholangiocarcinoma, but even after surgery, survival rates are unsatisfactory. Recently, several reports have suggested microvascular invasion (MiVi) is associated with poor postoperative prognosis in hepatocellular carcinoma (HCC). We considered that MiVi might be associated with poor clinical outcomes in patients with surgically resectable cholangiocarcinoma.The records of 91 patients who underwent resection with curative intent for cholangiocarcinoma at Inha University Hospital from 2007 to 2017 were comprehensively reviewed for clinicopathological characteristics, DFS, and overall survival (OS) relations between these factors and the presence of MiVi.Forty-nine of the 91 study subjects had MiVi and 42 did not. Median overall survivals were 492 days in the MiVi group and 1008 days in the noMiVi group and median DFSs were 367 days and 760 days, respectively. Cumulative survival ratio and recurrence incidence rates were significantly different in the 2 groups (P = .012). Multivariable analysis showed the presence of MiVi was an independent risk factor of OS (hazard ratio [HR] 3.34; 95% confidence interval [CI], 1.40-7.97; P = .007).Cholangiocarcinoma is known to have a poor prognosis. When microvascular invasion remains after surgery it is associated with poor clinical outcomes.

Citing Articles

MiR-380 inhibits the proliferation and invasion of cholangiocarcinoma cells by silencing LIS1.

Wei Z, Xu B, Yin Y, Chang J, Li Z, Zhang Y Cancer Cell Int. 2024; 24(1):129.

PMID: 38582841 PMC: 10998336. DOI: 10.1186/s12935-024-03241-4.


Nomogram based on preoperative clinical and MRI features to estimate the microvascular invasion status and the prognosis of solitary intrahepatic mass-forming cholangiocarcinoma.

Chen S, Wan L, Zhao R, Peng W, Liu X, Li L Abdom Radiol (NY). 2023; 49(2):425-436.

PMID: 37889266 DOI: 10.1007/s00261-023-04079-6.


Hypertension control and end-stage renal disease in atrial fibrillation: a nationwide population-based cohort study.

Kwon S, Lee S, Choi E, Jung J, Han K, Oh S Clin Res Cardiol. 2021; 111(3):284-293.

PMID: 34216251 DOI: 10.1007/s00392-021-01899-8.

References
1.
Fan B, Malato Y, Calvisi D, Naqvi S, Razumilava N, Ribback S . Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest. 2012; 122(8):2911-5. PMC: 3408746. DOI: 10.1172/JCI63212. View

2.
DeOliveira M, Cunningham S, Cameron J, Kamangar F, Winter J, Lillemoe K . Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007; 245(5):755-62. PMC: 1877058. DOI: 10.1097/01.sla.0000251366.62632.d3. View

3.
Yamamoto M, Takasaki K, Otsubo T, Katsuragawa H, Katagiri S . Recurrence after surgical resection of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg. 2001; 8(2):154-7. DOI: 10.1007/s005340170039. View

4.
Amini N, Ejaz A, Spolverato G, Maithel S, Kim Y, Pawlik T . Management of lymph nodes during resection of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: a systematic review. J Gastrointest Surg. 2014; 18(12):2136-48. DOI: 10.1007/s11605-014-2667-1. View

5.
Khan S, Davidson B, Goldin R, Heaton N, Karani J, Pereira S . Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut. 2012; 61(12):1657-69. DOI: 10.1136/gutjnl-2011-301748. View